Published in Cancer Weekly, March 22nd, 2005
The agreement provides Prolexys with exclusive, worldwide rights to a patent estate covering selective antitumor compounds discovered by Dr. Brent Stockwell, a former Whitehead Fellow, now an assistant professor of Biological Sciences and Chemistry at Columbia University.
Additional intellectual property was developed by Stockwell and scientists at Prolexys as part...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.